Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Berghuis AY, Pijnenborg JFA, Boltje TJ, Pijnenborg JMA. Sialic acids in gynecological cancer development and progression: impact on diagnosis and treatment. Int J Cancer. 2022;150(4):678–687. doi:10.1002/ijc.33866
   PubMed Web of Science ®Google Scholar
• Thurlow JS, Joshi M, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52(2):98–107. doi:10.1159/000514550
   PubMed Web of Science ®Google Scholar
• Calice-Silva V, Hussein R, Yousif D, et al. Associations between global population health indicators and dialysis variables in the Monitoring Dialysis Outcomes (MONDO) consortium. Blood Purif. 2015;39(1–3):125–136. doi:10.1159/000368980
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Silvestris N, Santoro A, et al. Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Societa Italiana di Nefrologia (SIN). ESMO Open. 2017;2(3):e000167. doi:10.1136/esmoopen-2017-000167
   PubMed Web of Science ®Google Scholar
• Gotta V, Dao K, Rodieux F, Buclin T, Livio F, Pfister M. Guidance to develop individual dose recommendations for patients on chronic hemodialysis. Expert Rev Clin Pharmacol. 2017;10(7):737–752. doi:10.1080/17512433.2017.1323632
   PubMed Web of Science ®Google Scholar
• Tomita M, Aoki Y, Tanaka K. Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs. Clin Pharmacokinet. 2004;43(8):515–527. doi:10.2165/00003088-200443080-00002
   PubMed Web of Science ®Google Scholar
• Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21(7):1395–1403. doi:10.1093/annonc/mdp598
   PubMed Web of Science ®Google Scholar
• Leung TV, Hughes ME, Cambareri CG, Rubin DJ, Eaby-Sandy B. Systemic treatments for lung cancer patients receiving hemodialysis. J Adv Pract Oncol. 2018;9(6):614–629. doi:10.1111/j.1525-1438.2007.01048.x
   PubMedGoogle Scholar
• Li YF, Fu S, Hu W, et al. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007;17(4):739–763. doi:10.1111/j.1525-1438.2007.00847.x
   PubMed Web of Science ®Google Scholar
• Wada T, Fukuda T, Kawanishi M, et al. Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: a case report. Biomed Rep. 2016;5(2):199–202. doi:10.3892/br.2016.714
   PubMedGoogle Scholar
• Matsuo N, Maruta M, Tsuruyama M, et al. 維持血液透析中の進行性食道がん患者にネダプラチンで化学療法を行った1症例 [A case of advanced esophageal cancer treated with nedaplatin in a patient undergoing maintenance hemodialysis]. Yakugaku Zasshi. 2020;140(3):449–453. Japanese. doi:10.1248/yakushi.19-00227
   PubMed Web of Science ®Google Scholar
• Gori S, Lunardi G, Inno A, et al. Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis. Clin Colorectal Cancer. 2014;13(4):260–263. doi:10.1016/j.clcc.2014.09.003
   PubMed Web of Science ®Google Scholar
• Woo MH, Gregornik D, Shearer PD, Meyer WH, Relling MV. Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol. 1999;43(1):92–96. doi:10.1007/s002800050868
   PubMed Web of Science ®Google Scholar
• Hochegger K, Lhotta K, Mayer G, Czejka M, Hilbe W. Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant. 2007;22(1):289–290. doi:10.1093/ndt/gfl498
   PubMed Web of Science ®Google Scholar
• Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:71–97. doi:10.1016/s0076-6879(05)91004-5
   PubMed Web of Science ®Google Scholar
• Fulton MD, Najahi-Missaoui W. Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci. 2023;24(7):6615. doi:10.3390/ijms24076615
   PubMed Web of Science ®Google Scholar
• Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002;61(4):1495–1501. doi:10.1046/j.1523-1755.2002.00279.x
   PubMed Web of Science ®Google Scholar
• Carlson L, Goren MP, Bush DA, et al. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms’ tumor. Cancer Chemother Pharmacol. 1998;41(2):140–146. doi:10.1007/s002800050720
   PubMed Web of Science ®Google Scholar
• Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review. Cancer Sci. 2021;112(7):2607–2624. doi:10.1111/cas.14933
   PubMed Web of Science ®Google Scholar
• Kiani A, Kohne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol. 2003;51(3):266–270. doi:10.1007/s00280-003-0574-3
   PubMed Web of Science ®Google Scholar
• Hann A, Nosalski E, Hermann PC, Egger J, Seufferlein T, Keller F. Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review. Clin Nephrol. 2018;90(2):125–141. doi:10.5414/cn109327
   PubMed Web of Science ®Google Scholar
• Yeung J, Vaughan E, Chadban S, Saunders J, Thiagarajah N, Brown C. High-dose intravenous methotrexate with high-flux, extended-hours haemodialysis in treatment of primary central nervous system, post-transplant lymphoproliferative disorder and end-stage kidney disease: a case report. Nephrology. 2018;23(11):1063–1064. doi:10.1111/nep.13254
   PubMed Web of Science ®Google Scholar
• Langenegger T, Wahl P, Schiesser D, Thurlimann B. Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. Breast Cancer Res Treat. 2006;100(2):177–181. doi:10.1007/s10549-006-9243-7
   PubMed Web of Science ®Google Scholar
• Nakatsuji H, Sakaki M, Hamao T. 血液透析患者に発症した精巣悪性リンパ腫の1例 [Primary testicular malignant lymphoma in a hemodialysis patient: a case report]. Hinyokika Kiyo. 2015;61(2):67–70. Japanese.
   PubMedGoogle Scholar
• Kimakura M, Abe T, Nagahara A, et al. Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase. Anticancer Drugs. 2016;27(4):364–368. doi:10.1097/CAD.0000000000000334
   PubMed Web of Science ®Google Scholar
• Moore KJ, Snow S, Wood LA. Delivering chemotherapy to a metastatic poor risk testicular cancer patient on hemodialysis. Curr Oncol. 2022;29(3):1808–1812. doi:10.3390/curroncol29030148
   PubMed Web of Science ®Google Scholar
• Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979;63(9–10):1515–1521.
   PubMedGoogle Scholar
• Tanabe N, Goto M, Morita H, et al. Pharmacokinetics of cis-diammine-dichlor-platin in a hemodialysis patient. Cancer Invest. 1991;9(6):629–635. doi:10.3109/07357909109039874
   PubMed Web of Science ®Google Scholar
• Sturn W, Sanwald R, Ehninger G. Pharmakokinetik von Cisplatin bei chronischer Hämodialyse-Behandlung [Pharmacokinetics of cisplatin in long-term hemodialysis treatment]. Dtsch Med Wochenschr. 1989;114(9):337–339. German. doi:10.1055/s-2008-1066599
   PubMedGoogle Scholar
• Tomita M, Kurata H, Aoki Y, Tanaka K, Kazama JJ. Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs. 2001;12(5):485–487. doi:10.1097/00001813-200106000-00010
   PubMed Web of Science ®Google Scholar
• Watanabe R, Takiguchi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer. 2003;88(1):25–30. doi:10.1038/sj.bjc.6600687
   PubMed Web of Science ®Google Scholar
• Bednarek A, Mykala-Ciesla J, Pogoda K, et al. Limitations of systemic oncological therapy in breast cancer patients with chronic kidney disease. J Oncol. 2020;2020:7267083. doi:10.1155/2020/7267083
   PubMed Web of Science ®Google Scholar
• Kodama J, Sasaki A, Masahiro S, et al. Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. Oncol Lett. 2010;1(3):511–513. doi:10.3892/ol_00000090
   PubMed Web of Science ®Google Scholar
• Matoba S, Sawada T, Toda S, et al. 透析患者でのmFOLFOX6 の使用経験 [Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. Gan To Kagaku Ryoho. 2008;35(4):673–675. Japanese.
   PubMedGoogle Scholar
• Ohnishi T, Kanoh T, Shiozaki K, et al. 慢性腎不全を有する大腸癌症例に対する血液透析併用FOLFOX 4療法の1例 [FOLFOX 4 in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure]. Gan To Kagaku Ryoho. 2007;34(8):1299–1302. Japanese.
   PubMedGoogle Scholar
• Mori M, Takeda E, Sakai K, et al. 腎機能低下患者に発症した非小細胞肺癌に対しCarboplatin+Weekly Paclitaxelが著効した1例 [A case of non-small cell lung carcinoma successfully treated with carboplatin and weekly paclitaxel under renal dysfunction]. Gan To Kagaku Ryoho. 2004;31(12):2061–2064. Japanese.
   PubMedGoogle Scholar
• Watanabe M, Aoki Y, Tomita M, et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol. 2002;84(2):335–338. doi:10.1006/gyno.2001.6527
   PubMed Web of Science ®Google Scholar
• Mencoboni M, Olivieri R, Vannozzi MO, Schettini G, Viazzi F, Ghio R. Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient. Chemotherapy. 2006;52(3):147–150. doi:10.1159/000092903
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN guidelines® insights: ovarian cancer, version 3.2022. J Natl Compr Canc Netw. 2022;20(9):972–980. doi:10.6004/jnccn.2022.0047
   PubMedGoogle Scholar
• Green AE, Rose PG. Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine. 2006;1(3):229–239.
   PubMed Web of Science ®Google Scholar
• de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44(11):1135–1164. doi:10.2165/00003088-200544110-00003
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang XC, Yu SF, et al. Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. BMC Cancer. 2015;15:917. doi:10.1186/s12885-015-1932-3
   PubMed Web of Science ®Google Scholar
• Urquhart BL, Freeman DJ, Spence JD, House AA. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis. 2007;49(1):109–117. doi:10.1053/j.ajkd.2006.10.002
   PubMed Web of Science ®Google Scholar
• Mutsando H, Fahim M, Gill DS, et al. High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. Am J Blood Res. 2012;2(1):66–70.
   PubMedGoogle Scholar
• Olson KRE. Poisoning & Drug Overdose. In: Lange Medical Books. 5th ed. New York, N.Y: McGraw-Hill; 2007.
   Google Scholar
• South AM. Primary renal diffuse large B-Cell lymphoma causing haemodialysis-dependent nephromegaly in a child. BMJ Case Rep. 2018;2018. doi:10.1136/bcr-2018-226328
   PubMedGoogle Scholar
• Squibb BM. Etopophos (etoposide phosphate) package insert. Available from: https://packageinserts.bms.com/pi/pi_etopophos.pdf. Accessed June 6, 2023.
   Google Scholar
• Haraguchi N, Satoh H, Ogawa R, Hashimoto Y, Sekizawa K. Chemotherapy in a patient with small-cell lung cancer undergoing haemodialysis. Clin Oncol. 2005;17(8):663. doi:10.1016/j.clon.2005.05.003
   Web of Science ®Google Scholar
• Takayama T, Haga I, Nakamura A, Asami K. 血液透析患者のStage Ⅳ大腸癌に対しBevacizumab+UFT 療法が有効であった4 例 [Bevacizumab plus UFT regimen for four patients with stage colorectal cancer receiving hemodialysis]. Gan To Kagaku Ryoho. 2020;47(7):1117–1119. Japanese.
   PubMedGoogle Scholar
• Gao F, Cong X, Liu Z. Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: a case report. Medicine. 2020;99(40):e22637. doi:10.1097/MD.0000000000022637
   PubMed Web of Science ®Google Scholar
• Rolfo C, de Vos-Geelen J, Isambert N, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment. Clin Pharmacokinet. 2019;58(9):1165–1174. doi:10.1007/s40262-019-00754-4
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 135565082, Talazoparib. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Talazoparib. Accessed June 20, 2023.
   Google Scholar
• Cheun H, Kim M, Lee H, Oh KH, Keam B. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Invest New Drugs. 2019;37(3):579–583. doi:10.1007/s10637-018-0673-y
   PubMed Web of Science ®Google Scholar
• Chang R, Shirai K. Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Rep. 2016;2016. doi:10.1136/bcr-2016-216426
   Google Scholar
• Cavalcante L, Amin A, Lutzky J. Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease. Cancer Manag Res. 2015;7:47–50. doi:10.2147/CMAR.S73389
   PubMed Web of Science ®Google Scholar
• Gettman L. New drug update: dostarlimab, loncastuximab tesirine, and aducanumab. Sr Care Pharm. 2022;37(1):9–16. doi:10.4140/TCP.n.2022.9
   PubMedGoogle Scholar
• Panoilia E, Schindler E, Samantas E, et al. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol. 2015;75(4):791–803. doi:10.1007/s00280-015-2701-3
   PubMed Web of Science ®Google Scholar
• Garnier-Viougeat N, Rixe O, Paintaud G, et al. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant. 2007;22(3):975. doi:10.1093/ndt/gfl664
   PubMed Web of Science ®Google Scholar
• Vitale MG, Baldessari C, Milella M, et al. Immunotherapy in dialysis-dependent cancer patients: our experience in patients with metastatic renal cell carcinoma and a review of the literature. Clin Genitourin Cancer. 2019;17(5):e903–e908. doi:10.1016/j.clgc.2019.06.009
   PubMed Web of Science ®Google Scholar
• Piacentini F, Omarini C, Barbieri E. Lapatinib and renal impairment: a case report. Tumori. 2013;99(3):e134–5. doi:10.1700/1334.14823
   PubMedGoogle Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 3385, Fluorouracil. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/3385#section=Absorption-Distribution-and-Excretion. Accessed June 22, 2023.
   Google Scholar